This study found a high prevalence of telogen effluvium among patients hospitalized for severe COVID-19, with most experiencing early onset and eventual complete hair regrowth.
January 2026 in “Archives of Dermatological Research” This study found that patients who were hospitalized for COVID-19 were more likely to develop telogen effluvium, a type of hair loss, compared to those treated as outpatients, suggesting a link between COVID-19 severity and this condition.
January 2022 in “Journal of Drug Delivery and Therapeutics” This study reported that all ten COVID-19 patients experienced early onset of Telogen effluvium within three months of infection, after recovering without hospitalization.
April 2023 in “Clinical dermatology review” This study found that 72% of patients who recovered from COVID-19 during the second wave reported experiencing significant hair loss, characteristic of telogen effluvium.
8 citations
,
February 2022 in “Journal of Clinical Medicine” This study found that a notable percentage of COVID-19 patients experienced post-infection telogen effluvium, although no significant associations with infection-related factors were identified.